QT Imaging is a privately held technology company engaged in the research, development and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images.
Approximately 39 million women, in the United States, get mammograms every year (source: CDC). For every 1 woman with cancer, 19 more will be told they might have cancer when they don’t. The cost, time, and psychological distress takes an enormous toll. We exist to change the paradigm of breast imaging and to keep women from going through the trauma of this journey. It’s why the FDA granted clearance for the QTscan as an adjunct to mammography, and the National Institutes of Health (NIH) awarded over $15 million in funding for QT Imaging research.
QT Imaging is founded and led by a medical doctor and managed by some of the best talent in their fields.
Dr. Klock has served as Chief Executive Officer of the Company since 2014 and as Managing Director, Manager and Founder of the Company since 2011. Prior to QT Imaging, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and eight granted patents.
Margaret Donigan brings strategy, investing, and operating experience to the company with particular focus on driving shareholder value. Prior to joining QT Imaging, she spent over a decade in middle market private equity, leading strategy development and making principal investments in more than a dozen companies, covering a variety of industries including healthcare. Ms. Donigan served as Executive Vice President of Corporate Development at Paradigm Tax Group, a company for which she led the recapitalization and served on the Board. She received her B.A. from Yale University and earned her MBA. in Finance and Operations Management from the Wharton School at the University of Pennsylvania, where she graduated as a Palmer Scholar.
For over three decades Mr. Pirshafiey has developed products and businesses for domestic and multinational firms. Mr. Pirshafiey’s creativity, innovative problem-solving skills, and entrepreneurial mindset have provided professional, technical, and business solutions to many start-ups and mature companies. He has previously founded and managed two companies with the mission to provide sustainable practices to industries such as medical devices, automotive, aerospace, high-tech, consumer products, and robotics (brief client list: Johnson & Johnson, Siemens, Edwards Life Sciences, Autoliv, TRW). Mr. Pirshafiey has 16 inventions filed with the US patent office, holds a Bachelor of Science in Aeronautical Engineering, and an MBA with specialization in Entrepreneurship.
Ms. Rudy is a graduate from UCLA with a BS in Mathematics and a Specialization in Computing. She worked for 2 ½ year at Ernst & Young in the audit practice in San Francisco where she obtained her CPA license. She then had the amazing opportunity to work for 21 years at Lucasfilm Ltd. in the Corporate Accounting group where she was the Assistant Controller. While there she was responsible for all the day-to-day accounting as well as annual audits, consolidation of 20+ legal entities, foreign production audits, system implementations and inventory of Star Wars costumes.
Dr. Malik has over ten years of experience in research, development, and translation of medical devices, both in academia and industry. He is an expert in leading and directing efforts in image and data science and has a track record of successfully leading innovation for medical imaging products, directing research strategy and navigating FDA pathways. Dr. Malik received a BS degree in engineering sciences from GIK Institute, Pakistan, and MS and PhD degrees in electrical and biomedical engineering from Texas A&M University. He has published 23 peer-reviewed papers and over 40 conference presentations.
Dr. Wiskin was co-founder of the winner of the 2005 Stoel-Rives Innovation Award for Medical Devices and shared “Utah Best of State” Science and Technology: Medical Innovation, which was then acquired by QT Imaging in 2012. As Principal Scientist he was involved in the FDA clearance for the first transmission ultrasound tomography of the breast and is actively involved in orthopedic/whole-body cutting-edge research, quantitative breast imaging, and analysis of images.
Dr. Wiskin is an author/co-author on 14 Patents, with several additional patents pending, and he has over 100 peer reviewed papers, book chapters, and presentations, including anchor talks at IEEE and Acoustical Society of America International Symposia.
He has studied the mathematics and physics of wave propagation (EM, acoustic, elastic, quantum) and inverse scattering for over 35 years, and has been elected to the SPIE Medical Imaging Ultrasound Tomography Conference Steering Committee and the IEEE International Ultrasound Symposium Medical Ultrasound Technical Program Committee.
Dr. Wiskin received a Bachelor of Mathematics (Honors, Math & Physics) from the University of Waterloo, Canada, a MSc in Biomathematics from Dalhousie University, Canada, and a Ph.D. in Mathematics from the University of Utah. He has also received a Descartes Fellowship, University of Waterloo, Graduate Research Fellowship, University of Utah, and was co-author of “Best Paper of the year,” in Computers. and Chemical Eng.
Mr. Ruiz has more than 20 years of experience in information technology. Prior to joining QT Imaging, Mr. Ruiz held a variety of positions with increasing responsibility addressing end user computing, global IT infrastructure, data centers, ERP administration, and service management. He has a strong background in ITIL, team development, and process standardization and optimization.
The company is managed by a Board of Managers. Each member has achieved the highest level of success in their field and offers a unique skill set and a valuable strategic contribution.
John C. Klock, M.D. has served as Chief Executive Officer of the Company since 2014 and as Managing Director, Manager and Founder of the Company since 2011.
Prior to QT Imaging, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions.
Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and has 8 granted patents.
Randall A. Mackey was appointed as a Manager of the Company on January 16, 2020. Mr. Mackey has served as Secretary of the Company since December 17, 2014. Mr. Mackey has served as President of the Salt Lake City law firm of Mackey Price Law, a Utah corporation, since 2018. From 1989 to 2017, Mr. Mackey served as President of the Salt Lake City law firm of Mackey Price & Mecham and its predecessor firms. From 1982 to 1989, Mr. Mackey was a shareholder, a vice president, and a director of the Salt Lake City law firm of Fabian & Clendenin (now Fabian VanCott) and, from 1977 to 1979, was an associate of that firm. From 1977 to 1979, Mr. Mackey was associated with the Washington D.C. law firm of Hogan & Hartson (now Hogan Lovells).
Mr. Mackey graduated magna cum laude and Phi Beta Kappa from the University of Utah in 1968, with a Bachelor of Science degree in Economics. He then received an M.B.A. degree from the Harvard Business School in 1970. Mr. Mackey received his Juris Doctor (J.D.) degree from Columbia Law School in 1975. In 1977, he received a Bachelor of Civil Law degree (a graduate law degree equivalent to an American LL.M. degree) from Oxford University in England.
Richard J. Stanley was appointed as a Manager of the Company on January 16, 2020. Mr. Stanley is an Associate Professor of Chemistry at Wagner College and spent 22 years as a chemical engineer for Proctor and Gamble. He has served as a member of SCORE (part of the Small Business Association) for 30 years. Mr. Stanley has combined his passion for baseball and interest in the global community through his work with a school in Uganda which brings educational opportunities and the benefits of sports to under served children. He holds a Master in Chemistry and an MBA in International Marketing.